Revvity (RVTY) has garnered attention due to a blend of events. A surge in their actual Q4 results, satisfactory outlook, and an association with Eli Lilly for AI drug discovery promoted increased leaps in their stocks. Elevated Earnings per Share (EPS) and revenue guidance, along with an amplified 2025 profit forecast range, had a positive impact on investor outlook. This pharmaceutical giant is expected to report a steep Q4 revenue of $772 million. A valuation reassessment suggested by current share price resurgence points towards the company's underexplored potential. A clear rebound is seen in RVTY’s stocks, with a 6.4% lift after the Lilly integration, and an expectation to hit their Q4 guidance with a 6% revenue growth. However, they've seen mixed reviews from firm Barclays and TD Cowen, who continue to support RVTY, while Goldman Sachs retains a neutral perspective. Their Sanofi partnership has pushed growth outlooks further. While their earnings have been trending downwards over the past five years, a boost in recent earnings provides hope for a turnabout.
Revvity RVTY News Analytics from Tue, 24 Jun 2025 07:00:00 GMT to Fri, 16 Jan 2026 08:00:00 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor 4
